| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0007 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.001 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.003 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.095 | 0.004 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.097 | 0.004 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.096 | 0.006 |